Gossamer Bio, Inc.GOSSNASDAQ
Loading

Latest News

GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails
prnewswire.com

GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails

Gossamer Bio CEO Expressed Optimism About PROSERA Trial Outcome; the Study Missed Its Primary Endpoint Months Later NEW YORK, March 18, 2026 /PRNewswire/ -- Gossamer Bio, Inc. (NASDAQ: GOSS) shareholders suffered significant losses when the Company disclosed that its Phase 3 PROSERA study of seralutinib missed its primary 6-minute walk distance endpoint in pulmonary arterial hypertension. In May 2025, CEO Faheem Hasnain told investors the Company was "more optimistic than ever about the likelihood of achieving positive results.

Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
businesswire.com

Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a g.

Investigation Alert: Gossamer Bio, Inc. (GOSS) Under Scrutiny - Contact Levi & Korsinsky for Details
newsfilecorp.com

Investigation Alert: Gossamer Bio, Inc. (GOSS) Under Scrutiny - Contact Levi & Korsinsky for Details

New York, New York--(Newsfile Corp. - March 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer Bio, Inc.") concerning potential violations of the federal securities laws. Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Company's pivotal Phase 3 trial evaluating the drug in pulmonary arterial hypertension.

Gossamer Bio (NASDAQ:GOSS) versus Actuate Therapeutics (NASDAQ:ACTU) Critical Survey
defenseworld.net

Gossamer Bio (NASDAQ:GOSS) versus Actuate Therapeutics (NASDAQ:ACTU) Critical Survey

Actuate Therapeutics (NASDAQ: ACTU - Get Free Report) and Gossamer Bio (NASDAQ: GOSS - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings. Institutional and Insider Ownership 81.2% of Gossamer

Lost Investment in Gossamer Bio, Inc. (GOSS)? Levi & Korsinsky Launches Securities Fraud Investigation
newsfilecorp.com

Lost Investment in Gossamer Bio, Inc. (GOSS)? Levi & Korsinsky Launches Securities Fraud Investigation

New York, New York--(Newsfile Corp. - March 9, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. ("Gossamer Bio, Inc.") (NASDAQ: GOSS) concerning potential violations of the federal securities laws. Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Company's pivotal Phase 3 trial evaluating the drug in pulmonary arterial hypertension.

GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP
prnewswire.com

GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP

Gossamer Bio Provided Forward-Looking Trial Guidance While Omitting the Heightened Statistical Threshold That Made a Miss More Likely NEW YORK, March 4, 2026 /PRNewswire/ -- Gossamer Bio, Inc. (NASDAQ: GOSS) lost more than 60% of its value after the Company's Phase 3 PROSERA trial of seralutinib missed its primary endpoint. In May 2025, CEO Faheem Hasnain told investors on the Q1 2025 earnings call: "We anticipate announcing top-line results in February 2026" -- guidance that set expectations for a meaningful readout.

Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Gossamer Bio, Inc. (GOSS)
newsfilecorp.com

Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Gossamer Bio, Inc. (GOSS)

New York, New York--(Newsfile Corp. - March 3, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. ("Gossamer Bio, Inc.") (NASDAQ: GOSS) concerning potential violations of the federal securities laws. Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Company's pivotal Phase 3 trial evaluating the drug in pulmonary arterial hypertension.